Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma
Dur/Tre therapy may better preserve liver function compared with Atez/Bev therapy in patients with unresectable HCC.
Authors
- Kenta Motomura (ORCID: https://orcid.org/0000-0002-7515-099X)
- Hideo Suzuki (ORCID: https://orcid.org/0000-0002-1469-7449)
- Masayoshi Yada (ORCID: https://orcid.org/0000-0002-1129-5380)
- Akifumi Kuwano (ORCID: https://orcid.org/0000-0001-9397-8056)
- Masatake Tanaka (ORCID: https://orcid.org/0000-0001-7461-0678)
- Junro Takahira
Institutions
- Ichinomiya Kenshin College (JP)
- Aso Iizuka Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.21873/anticanres.17552
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00